Latest Benign Prostatic Hyperplasia (BPH) News
Study confirms small, but significant increases in the risks of these mental health problems among men taking the medication.
Longer use of finasteride at a dosage of 1.25 mg/day or less among men younger than 42 years is associated with greater risk, study finds.
The finasteride and dutasteride recipients had significantly less mean blood loss than the placebo group.
Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.
Poor baseline functional status and having a Foley catheter preoperatively were associated with greater risk of TURP or TULIP failure.
New findings confirm previous reports.
Use of 5ARIs for BPH was associated with a statistically significant increased, pooled relative risk for sexual dysfunction.
Patients' pre-existing urinary problems influenced their perceptions of symptom relief after prostate cancer treatment.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
Study documents significant improvements in frequency, urgency, and nocturia.
Patients experienced a sustained decrease in AUA Symptom Score, and 95% of patients report being satisfied or very satisfied with the procedure.
Significant improvements in lower urinary tract symptoms are durable to 24 months, data show.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
New data show that the minimally invasive procedure is superior overall to TURP for treating BPH-related lower urinary tract symptoms.
Procedure partially blocks blood flow to the gland and appears to ease the need to urinate.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)